Marc Scherlinger

OX40L/OX40 axis impairs follicular and natural Treg function in human SLE

C. Jacquemin, Jean‐François Augusto, Marc Scherlinger et al. · JCI Insight · 2018 · 88 citations · Full text

Life Sciences, Immunology, Pathobiology +17

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Marc Scherlinger, Vincent Germain, Céline Labadie et al. · Joint Bone Spine · 2017 · 82 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Refining “Long-COVID” by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection

Marc Scherlinger, Renaud Felten, Floriane Gallais et al. · Infectious Diseases and Therapy · 2021 · 78 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

Marc Scherlinger, Emmanuel Langlois, Vincent Germain et al. · Seminars in Arthritis and Rheumatism · 2018 · 62 citations · Full text

Management, Sociology, Technology Transfer +8

Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis

Antoine Grillon, Marc Scherlinger, Pierre-Hugues Boyer et al. · Seminars in Arthritis and Rheumatism · 2018 · 59 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +11